EP Patent

EP1791520A2 — Controlled release nanoparticle active agent formulation dosage forms and methods

Assigned to Alza Corp · Expires 2007-06-06 · 19y expired

What this patent protects

A controlled-release dosage form comprising a cavity-defining wall, an expandable layer, a drug layer on the basis of active agent-containing nanoparticles absorbed onto porous particles.

USPTO Abstract

A controlled-release dosage form comprising a cavity-defining wall, an expandable layer, a drug layer on the basis of active agent-containing nanoparticles absorbed onto porous particles.

Drugs covered by this patent

bupropion-hydrobromide (BUPROPION HYDROBROMIDE)

Patent Metadata

Patent number: EP1791520A2
Jurisdiction: EP
Classification: —
Expires: 2007-06-06
Drug substance claim: No
Drug product claim: No
Assignee: Alza Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.